CVI2017 Challenging Cases - Ahmad Zankar, MD

CVI2017 Challenging Cases - Ahmad Zankar, MD

CVI2017 Challenging Cases - Ali Nazmi Calik, MDПодробнее

CVI2017 Challenging Cases - Ali Nazmi Calik, MD

CVI2017 Challenging Case - Omer Iftikhar, MDПодробнее

CVI2017 Challenging Case - Omer Iftikhar, MD

CVI2017 Challenging Cases - Abdulah Al Rifai, MDПодробнее

CVI2017 Challenging Cases - Abdulah Al Rifai, MD

CVI2017 Challenging Case - Nilesh Patel, MDПодробнее

CVI2017 Challenging Case - Nilesh Patel, MD

CVI2017 Challenging Case - Leif Christianson, MDПодробнее

CVI2017 Challenging Case - Leif Christianson, MD

CVI2017 Challenging Case - Sara C. Martinez, MDПодробнее

CVI2017 Challenging Case - Sara C. Martinez, MD

CVI2017 Challenging Case - Shoaib Saya, MDПодробнее

CVI2017 Challenging Case - Shoaib Saya, MD

CVI2017 Challenging Case - Leon Varjabedian, MDПодробнее

CVI2017 Challenging Case - Leon Varjabedian, MD

CVI2017 Challenging Case - Konstantinos Charitakis, MDПодробнее

CVI2017 Challenging Case - Konstantinos Charitakis, MD

CVI2017 Challenging Case - Mohamad Kabach, MD (case 1)Подробнее

CVI2017 Challenging Case - Mohamad Kabach, MD (case 1)

CVI2017 Challenging Casey - Sahara Ismail, MDПодробнее

CVI2017 Challenging Casey - Sahara Ismail, MD

CVI2017 Challenging Case: One, Two and Three - Cheuk Ming Yan, MDПодробнее

CVI2017 Challenging Case: One, Two and Three - Cheuk Ming Yan, MD

CVI2017 Challenging Case - Mohamad Kabach, MD (case 2)Подробнее

CVI2017 Challenging Case - Mohamad Kabach, MD (case 2)

UKMLA AKT Medical Emergencies - Management and Complications | Multiple Choice QuestionsПодробнее

UKMLA AKT Medical Emergencies - Management and Complications | Multiple Choice Questions

UKMLA AKT Biliary Disease (Surgery) : Management and Complications | Multiple Choice QuestionsПодробнее

UKMLA AKT Biliary Disease (Surgery) : Management and Complications | Multiple Choice Questions

How is CT053 different from other BCMA-directed CAR T-cell therapies?Подробнее

How is CT053 different from other BCMA-directed CAR T-cell therapies?

Part 2: OR protocols, patient selection and operational measures—The road to recoveryПодробнее

Part 2: OR protocols, patient selection and operational measures—The road to recovery

Новости